BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

BOSTON--(BUSINESS WIRE)--Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicine demonstrating that calibration dramatically improves the accuracy and ...

Caris Life Sciences aims to standardize MET immunohistochemistry testing for non-squamous non-small cell lung cancer to enhance molecular insights and treatment personalization. MET protein expression ...

Hello. This is Mark Kris, from Sloan Kettering, continuing my discussion about the increasing precision of lung cancer therapies and the need for additional testing beyond our routine next-generation ...

BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Boston Cell Standards announced the publication this month of a Canadian national study testing the first reference standard for estrogen receptor (ER) ...

New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...

DENVER – Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry ...

Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project HER2 status was evaluated using ...

Background: Biomarker testing is essential for guiding first-line treatment decisions in metastatic non–small cell lung cancer (mNSCLC). Despite guideline recommendations, real-world testing patterns ...